TEVA Overview
Upcoming Projects (TEVA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TEVA)
-
Evaluating the current treatment landscape in Tardive Dyskinesia post Ingrezza and Austedo approval
Tickers: NBIX, TEVA
Executed On: Sep 06, 2019 at 12:00 PM EDT -
Checking in on the Migraine landscape and impact oral and IV CGRPs might have on prescribing.
Tickers: BHVN, AMGN, LLY, TEVA
Executed On: Mar 15, 2019 at 01:00 PM EDT -
Understanding how Vascepa fits in the prescription-based, pure EPA market in treating hypertriglyceridemia
Tickers: AMRN, TEVA, AZN, GSK
Executed On: Jul 28, 2017 at 01:00 PM EDT -
Checking the Launch: How is Ingrezza fairing in the early days of commercialization?
Tickers: NBIX, VRX, TEVA
Executed On: Jun 21, 2017 at 08:30 AM EDT -
Another Expert View: Discussing the Market Potential of Neurocrine's (NBIX) Ingrezza for Tardive Dyskinesia & Impact on Teva's Austedo
Tickers: NBIX, VRX, TEVA
Executed On: May 03, 2017 at 10:00 AM EDT -
Discussing the Market Potential of Neurocrine's (NBIX) Ingrezza for Tardive Dyskinesia After April 11th PDUFA
Tickers: NBIX, TEVA, VRX
Executed On: Apr 19, 2017 at 01:30 PM EDT -
Evaluating Scarcity & Value of Sterile Manufacturing Facilities
Tickers: TEVA, PFE
Executed On: Nov 01, 2016 at 11:00 AM EDT -
Evaluating the Chances of Approval and Market Potential for Alder's (ALDR) ALD403 in Treatment of Chronic Migraines and Frequent Episodic Migraines After Positive Phase 2b Data Readout
Tickers: ALDR, AMGN, TEVA
Executed On: Apr 13, 2016 at 11:00 AM EDT -
Can BELBUCA become the standard of care? How important is the Schedule 3 designation vs. other pain killers both for patients' health and prescribing?
Tickers: BDSI, TEVA, PFE, PTX, ENDP, Purdue Pharma
Executed On: Apr 04, 2016 at 03:00 PM EDT
Included with Membership
Expired Projects (TEVA)
-
A Second Opinion: Preparing for Eptinezumab's data in Chronic Migraine after study changes and additional data from Erenumab
Tickers: ALDR, AMGN, TEVA, NVS
Execute By: May 17, 2017 -
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016
Upcoming & Overdue Catalysts (TEVA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TEVA)
-
FDA approves Teva's (TEVA) generic Narcan nasal spray for opioid overdose
Ticker: TEVA
Occurred on: Apr 19, 2019 -
Top line data from PROMISE 2, a Phase 3 study of Eptinezumab in 1,500 Chronic Migraine patients
Tickers: ALDR, TEVA, AMGN
Occurred on: Feb 26, 2018 -
TEVA's NDA for SD-809 in Tardive Dyskinesia Granted PDUFA Date of August 30th
Ticker: TEVA
Occurred on: Aug 30, 2017 -
Phase 2 data of TV-45070 for Postherpetic neuralgia due 1H 2017
Tickers: XENE, TEVA
Occurred on: Jun 27, 2017 -
Teva's Vantrela ER Approved by FDA for Pain Management
Ticker: TEVA
Occurred on: Jan 18, 2017 -
Teva's Generic Version of Daiichi Sankyo's (DSNKY) Tribenzor Approved by FDA for Hypertension
Tickers: TEVA, DSNKY
Occurred on: Nov 07, 2016 -
The FDA has asked Teva to re-analyze blood levels of certain metabolites in a CRL for SD-809 NDA. Teva will submit its response in Q3
Ticker: TEVA
Occurred on: Oct 20, 2016 -
FDA Places Hold on Teva (TEVA) and Regeneron's (REGN) Phase 2b Trial Evaluating Fasinumab in Chronic Low Back Pain
Tickers: TEVA, REGN
Occurred on: Oct 17, 2016 -
FDA Sends Warning Letter to Teva Regarding Deficiencies in Hungarian Manufacturing Site
Ticker: TEVA
Occurred on: Oct 14, 2016 -
Teva (TEVA) Begins U.S Commercial Launch of RAJANI, a Generic Form of Bayer's (BAYRY) Oral Contraceptive Beyaz
Tickers: TEVA, BAYRY
Occurred on: Oct 12, 2016 -
Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)
Ticker: TEVA
Occurred on: Sep 22, 2016 -
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease
Ticker: TEVA
Occurred on: Sep 19, 2016 -
Teva (TEVA) Launches Generic Version of Merck's CUBICIN for Complicated Skin and Bloodstream Infections in U.S
Tickers: MRK, TEVA
Occurred on: Sep 15, 2016 -
Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE 40 mg
Ticker: TEVA
Occurred on: Aug 24, 2016 -
European Commission Grants Marketing Authorization for Teva’s CINQAERO (reslizumab)
Ticker: TEVA
Occurred on: Aug 18, 2016 -
Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition
Tickers: TEVA, Actavis Generics
Occurred on: Jul 27, 2016 -
Teva Receives CHMP Positive Opinion for CINQAERO (reslizumab)
Ticker: TEVA
Occurred on: Jun 24, 2016 -
TEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States
Tickers: TEVA, ATRS
Occurred on: Jun 23, 2016 -
Teva to complete phase 3 trial for SD-809 as a treatment for Chorea Associated With Huntington Disease in December 2015 (via Aspex acquisition)
Tickers: TEVA, ASPX
Occurred on: Apr 18, 2016 -
New business venture focused on generics in Japan to be established in or after April 2016; owned 51% by Teva and 49% by Takeda
Tickers: TEVA, TEVA.TA, TKPYY
Occurred on: Apr 01, 2016 -
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA (bendamustine hydrochloride) Injection
Tickers: TEVA, EGLT
Occurred on: Jan 28, 2016 -
TEVA Launches Generic Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the United States
Tickers: TEVA, TEVA.TA
Occurred on: Jan 05, 2016
Strategic Initiatives (TEVA)
-
Teva and Syqe Medical Sign Marketing Agreement for Medical Cannabis Inhaler
Tickers: TEVA, Syqe Medical
Announcement Date: Nov 28, 2016 -
Teva Expands Research Partnership with IBM to Develop Cognitive Computing Technologies to Enhance Drug Repurposing
Tickers: TEVA, IBM
Announcement Date: Oct 26, 2016 -
Teva (TEVA) Begins U.S Commercial Launch of RAJANI, a Generic Form of Bayer's (BAYRY) Oral Contraceptive Beyaz
Tickers: TEVA, BAYRY
Announcement Date: Oct 12, 2016 -
Teva (TEVA) and South Korean Celltrion Enter into Exclusive Partnership to Commercialize Biosimilars to Rituxan and Herceptin in the U.S and Canada
Tickers: TEVA, Celltrion
Announcement Date: Oct 06, 2016 -
Teva (TEVA) Divests Actavis Generics Assets in UK and Ireland Through $766MM Sale to Intas Pharmaceuticals
Tickers: TEVA, Accord Healthcare Limited, Actavis Generics, Intas Pharmaceuticals
Announcement Date: Oct 05, 2016 -
Teva (TEVA) Launches Generic Epzicom in U.S for Combination Treatment of HIV-1 Infection
Ticker: TEVA
Announcement Date: Sep 28, 2016 -
Teva (TEVA) and Regeneron (REGN) Agree to Global Commercialization and Development Deal for REGN's Fasinumab in Chronic Lower Back Pain
Tickers: TEVA, REGN
Announcement Date: Sep 20, 2016 -
Teva Completes Acquisition of Actavis Generics
Tickers: TEVA, AGN
Announcement Date: Aug 02, 2016 -
Impax Signs Definitive Agreements to Acquire Generic Products
Tickers: IPXL, TEVA
Announcement Date: Jun 21, 2016 -
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
Tickers: TEVA, AbCellera
Announcement Date: Feb 02, 2016